TRIAL DETAIL
A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Patients With Locally Advanced or Metastatic Solid Tumors
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Patients With Locally Advanced or Metastatic Solid Tumors |
|||
NCT#: |
||||
Conditions: |
Solid Tumors |
|||
Status: |
Ongoing, but not recruiting |
|||
Phase: |
1 |
Start Date 04/01/2012 |
Age of Trial (yrs) 12.1 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
Akt inhibitor + MEK inhibitor |
|||
Strategy: |
Block related tumor signal paths |
|||
Trial Type: |
GIST not specified. GIST patient enrollment unknown. |
|||
Other Protocol IDs: |
GE28079 |
|||
Sponsor: |
Genentech |
|||
Patient Contact: |
Please reference Study ID Number: GE28079
888-662-6728 (U.S. Only) genentechclinicaltrials@druginfo.com |
|||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
Oral |
|||
Trial Notes: |
||||
Trial Links |
Trial Results |
Drug Information |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
4100 John R |
Detroit |
MI |
48201 |
USA |
|
3322 West End Avenue |
Nashville |
TN |
37203 |
USA |
|
Boston |
MA |
02115 |
USA |